Previous 10 | Next 10 |
23andMe Holding Co. is gearing up to capitalize on its growing genetic database by investing in new business verticals and industry-first services. The company engages in dialogue with the FDA and watch groups to ensure that its personalized services do not violate current or future g...
SUNNYVALE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be pres...
23andMe (NASDAQ: ME) investors have had a bumpy ride in the last 12 months. The company's shares are down by more than 67%, quarterly revenue growth has slumped into the single digits, and profitability remains far out of reach. Nonetheless, enterprising investors may believe th...
As a genetic testing company, 23andMe Holding (NASDAQ: ME) is a futuristic business by default. There's nothing cooler than sending away a tube filled with your spit and getting (some of) the secrets of your genome unlocked and presented in a tidy report on your computer screen in r...
23andMe Holding Co. (ME) Q3 2022 Earnings Conference Call February 10, 2022 16:30 ET Company Participants Wade Walke - Vice President of Investor Relations Anne Wojcicki - Co-Founder & Chief Executive Officer Steve Schoch - Chief Financial Officer Kenneth Hillan - Head of Therapeutics Con...
Shares of 23andMe (NASDAQ:ME) are down 3% in post-market trading after the company's FQ3 2022 results missed on the bottom line. GAAP EPS of -$0.21 missed by $0.06. However, the company did increase the projected range for full year revenue for FY 2022, which will end on March 31, f...
23andMe press release (NASDAQ:ME): FQ3 GAAP EPS of -$0.21 misses by $0.06. Revenue of $56.89M (+2.5% Y/Y) beats by $2.59M. Shares -3.02%. For further details see: 23andMe GAAP EPS of -$0.21 misses by $0.06, revenue of $56.89M beats by $2.59M
Third quarter revenue of $57 million Therapeutics group advances first wholly-owned immuno-oncology antibody into clinical trials Vision of genetics-based primary care offers potential for millions of people to live healthier lives SUNNYVALE, Calif., Feb. 10, 2022 (GLOBE...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks are a notoriously volatile stock class. And with inflation concerns growing worse by the month, penny stocks could feel like a bridge too far at the moment. Interest rates are rising, putting pressure on ris...
SUNNYVALE, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 (FY2022) third quarter after the market clos...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...